Steve Kafka
Managing Partner of Section 32 and former president of Foundation Medicine
With a passion for working with exceptional scientists and creative business executives, Steve has built multiple companies with a focus on transforming and impacting patient care while creating exciting and rewarding professional opportunities for its employees.
Steve extends his medical technology expertise to several other ventures. He currently serves as the Executive Chairman for Thrive Earlier Detection, a biotechnology company that develops early detection tests for multiple types of cancer. Steve is also the Executive Chairman at the molecular technology company ArcherDX, Inc. which empowers physicians to apply high-quality genomics in daily clinical care.
Steve has held leadership roles with several pharmaceutical and biopharmaceutical companies, including Foundation Medicine, Aileron Therapeutics, and Infinity Pharmaceuticals.
Visit website: https://section32.com/steve-kafka-phd/
See also: Section 32 - venture capital firm investing at the frontiers of technology, healthcare and the life sciences.
Details last updated 29-Jul-2020
Steve Kafka News
Cancer genetics sequencing company harnesses big data
Business Insider - 14-Jan-2016
10 days to get a cancer patient’s comprehensive genomic profiling analysis. Details go into data...
Read more...